⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1065577 | 0.98 | ALDH1A1 (0.54) | — | |
| SCHEMBL5953248 | 0.93 | ALDH1A1 (0.54) | — | |
| Hydrochloric Acid SCHEMBL1066752 | 0.91 | ALDH1A1 (0.52) | — | |
| SCHEMBL21568850 | 0.91 | ALDH1A1 (0.52) | — | |
| SCHEMBL23471339 | 0.91 | ALDH1A1 (0.52) | — | |
| SCHEMBL1892585 | 0.85 | — | — | |
| SCHEMBL67905 | 0.83 | ALDH1A1 (0.58) | — | |
| Hydrochloric Acid SCHEMBL1067794 | 0.83 | — | — | |
| SCHEMBL4942719 | 0.81 | — | — | |
| SCHEMBL16845049 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-11-26 | — | — | US | disclosed |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2021-11-25 | — | — | US | disclosed |
| EP-3858814-A1 | NITROXOLINE PRODRUG AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-1602362-B1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | TAKEDA PHARMACEUTICAL (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2886530-A1 | ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-06-24 | — | — | EP | disclosed |
| EP-0882720-B1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-6130332-A | USING A GROUP 8 METAL CATALYST AND ALDEHYDES OR KETONE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| US-6127538-A | HYDROXYALKYLATION OF A TRIAMINO TRIAZINE DERIVATIVE HAVING AT LEAST ONE REACTIVE NITROGEN BY REACTING WHILE HEATING WITH AN ALKANEDIOL OR ITS ADDUCT IN THE PRESENCE OF HYDROGEN AND A METAL CATALYST; BY-PRODUCT INHIBITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0882720-A1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5780501-A | ADMINISTERING TO A MAMMAL | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| US-5780500-A | Anti-neurodegeneratively active 10-aminoaliphatyl-dibenzi b,f! oxepines | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997046549-A1 | ANTI-NEURODEGENERATIVELY EFFECTIVE XANTHENE DERIVATIVES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997045422-A1 | ANTI-NEURODEGENERATIVELY EFFECTIVE 10-AMINOALIPHATYL-DIBENZ[b,f]OXEPINE SALTS | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |